If you are not happy with the results below please do another search
Due to the immunological pathogenesis of IgA nephropathy (IgAN), patients used to be given immunosuppressive therapy; however, this was shown to have no long-term benefit over optimal supportive therapy.
Neurons, nerve cells in the brain, are central players in brain function. However, a key role for glia, long considered support cells, is emerging. A research group at the University of Basel has now discovered two new types of glial cells in the brain, by unleashing adult stem cells from their quiescent state. These new […]
The U.S. FDA has approved Aduhelm (aducanumab) developed by Biogen, Cambridge, Massachusetts, for the treatment of Alzheimer’s. Aduhelm was approved using the ‘accelerated approval pathway’.
The Native Antigen Company, part of LGC Clinical Diagnostics and one of the world’s leading suppliers of reagents that enables research into diagnostics and vaccines for emerging and endemic infectious diseases, won ‘The Best COVID-19 Responder’ at the OBN 2020 Awards. The award recognises the company’s outstanding contribution to the fight against COVID-19.
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, has received a patent from the Japan Patent Office for their oncolytic virus (OV) backbone VVcopTK-RR- that encodes one or more immune checkpoint inhibitors (ICIs).
Lunaphore Technologies, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, has appointed Matthias Weber, former President of Leica Biosystems, to its Board of Directors. Weber has been appointed to represent the interests of strategic investor PHC Holdings Corporation (PHCHD), who previously invested in Lunaphore through a Series C financing round in 2020.
Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, has completed a US$47 million financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners. The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform […]
Aptamer Group, the developer of Optimer Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, have entered into a strategic collaboration agreement. The agreement is to develop Optimer-drug conjugates for targeted drug delivery combining Aptamer Group’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.
Byondis has reported positive topline results from the Phase III TULIP study, a multi-centre, open-label, randomized clinical trial. The trial compared the efficacy and safety of the company’s antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) to physician’s choice treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer.
Celemics has partnered with Strand Life Sciences to develop a bioinformatics solution capable of providing users with an accelerated means of producing high-quality, in-class clinical genomics reports and enabling a complete sample-to-answer solution, including assayspecific variant filters.
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
